The second wave of the Corona pandemic has brought significant relief for a country suffering from a shortage of vaccines.
The Central Government has approved Bharat Immunological and Biological Limited (BIBCOL) in Bulandshahr, Uttar Pradesh, to manufacture the Covid-19 vaccine to increase vaccine production.
After this, BIBCOL has also tied up with Bharat Biotech. From August-September, the company will produce 20 million doses of ‘covaxin’ every month.
Ministry of Science and Technology approved three companies.
According to India TV, the Ministry of Science and Technology has said that to accelerate the production of indigenous vaccines in India, the government provides financial assistance to vaccine manufacturers under the Department of Biotechnology. Similarly, the Central Pharmaceutical Standards Control Organization has issued approval to three companies producing Bharat Biotech’s Covid-19 vaccine ‘covaxin’. BIBCOL is a significant company. This will speed up the production of vaccine.
BIBCOL was established in the year 1989
BIBCOL is located near Chaula village, nine kilometres from Bulandshahr district headquarters. The company currently produces polio vaccines, zinc dispensable tablets and diarrhoea management kits in the country.
The central government established this company in Bulandshahr in 1989 in collaboration with Russia. After this, from the year 1995-96, BIBCOL has started producing the vaccine for polis in the country. It is one of the leading companies in the country.
BIBCOL has got the responsibility of production of ‘Covaxin’
BIBCOL accounts for 60 per cent of the total polio vaccine production in the country. The company produces about 150 crore doses of polis every year. Because of the same production capacity of the company, the government and Bharat Biotech have entrusted it with the responsibility of producing ‘Covaxin’. The Indian Council of Medical Research (ICMR) and Bharat Biotech prepared the first indigenous corona vaccine, and It was a significant achievement for the country.
Got permission to produce ‘Covaxin’ – Shukla
BIBCOL Vice President RK Shukla said that the Union Health Ministry has issued permission for the production of ‘Covaxin’ and has also approved a budget of Rs 30 crore. He said that the company has also signed an MOU with Bharat Biotech for vaccine production. The company will start production of covaxin from August-September. For this, the technical team is engaged in gathering the necessary resources.
Covaxin will also be tested on children soon.
India Biotech vaccine will soon be ready for children of 2 to 18 years in India. The Subject Experts Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) on Tuesday approved the second and third stage clinical trials of covaxin on this age group. The trial will be conducted on 525 children in AIIMS Delhi, AIIMS Patna and Meditrina Institute of Medical Sciences Nagpur.